Rate My Professor Simon Lewis

Lewis’s integrated research program utilises neuroimaging, neurophysiology, neuropathology, chronobiology, neurogenetics, and peripheral biomarkers to evaluate symptoms such as dementia, gait disturbance, sleep-wake problems, and hallucinations. His work focuses on predicting disease onset, conducting disease-modifying drug trials, and improving treatments for neurodegenerative conditions. He leads multiple active projects, including trials on guanfacine for cognition in Parkinson’s disease, sodium selenate for progressive supranuclear palsy, and neuromelanin-sensitive imaging as biomarkers. Lewis has authored over 300 peer-reviewed papers, two books, and eight book chapters, with an h-index of 78 (Scopus) and over 35,000 citations (Google Scholar). Key publications include “Melatonin for rapid eye movement sleep behavior disorder in Parkinson’s disease: a randomised controlled trial” (2020, Movement Disorders), “Evidence for subtypes of freezing of gait in Parkinson’s disease” (2018, Movement Disorders), “An updated definition of freezing of gait” (2026, Nature Reviews Neurology), and “Visual hallucinations in Parkinson’s disease” (2025, Brain). He mentors junior doctors, nurses, and research students to build capacity in clinical and research fields.